Document Detail


Pharmacotherapy of obesity: clinical treatments and considerations.
MedLine Citation:
PMID:  23531960     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Obesity is a world-wide epidemic associated with significant morbidity and mortality which costs billions of dollars per year. The associated related conditions are many and include heart disease, stroke, type II diabetes mellitus, sleep apnea and certain types of cancer. Given that it is a multifactorial problem, the treatments must also address the numerous causes associated with the development of obesity. The neurohormonal regulation of feeding and energy is a complex system often necessitating modification through more than 1 pathway to achieve weight loss. Therefore, in addition to lifestyle changes, attenuation of caloric intake and increase in caloric expenditure, pharmacotherapies, including combination medications, may prove beneficial in its treatment. Adding to the current available pharmacotherapies for obesity, the Food and Drug Administration has recently approved 2 new combination medications known as lorcaserin (Belviq) and phentermine-topiramate (Qsymia). As with these and other medications used for weight loss, clinical cautions, side effects, precise review of patients' medical history and selecting the appropriate medication are imperative. Additionally, close follow-up is necessary in patients undergoing treatment for weight loss. As weight loss progresses, patients who are currently undergoing concomitant treatment for comorbid diabetes and hypertension need to be monitored for appropriate changes in medications used to treat those conditions. Weight loss is often accompanied by improvement in blood pressure and glucose levels and therefore resting blood pressure and fasting and/or postprandial plasma glucose levels should be monitored at follow-up. Although unique to each individual, the benefits of weight loss are substantial and can improve well-being and physical health.
Authors:
Kelly Anne Holes-Lewis; Robert Malcolm; Patrick M O'Neil
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of the medical sciences     Volume:  345     ISSN:  1538-2990     ISO Abbreviation:  Am. J. Med. Sci.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-27     Completed Date:  2013-05-17     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  0370506     Medline TA:  Am J Med Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  284-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Division of Endocrinology, Medical University of South Carolina, Charleston, SC 29425, USA. holeslew@musc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Obesity Agents / therapeutic use*
Benzazepines / therapeutic use
Drug Therapy, Combination
Fructose / analogs & derivatives,  therapeutic use
Humans
Obesity / drug therapy*
Phentermine / therapeutic use
Chemical
Reg. No./Substance:
0/Anti-Obesity Agents; 0/Benzazepines; 0H73WJJ391/topiramate; 122-09-8/Phentermine; 30237-26-4/Fructose; 637E494O0Z/lorcaserin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  All grown up: moving from pediatric to adult diabetes care.
Next Document:  Improving diabetes management with mobile health technology.